T790M mutation accounts for 30–60% of secondary EGFR point mutations in NSCLC patients who developed acquired resistance to 1st and 2nd generation of EGFR-TKIs [27,28,29]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.